These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 21356258)
1. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome. Ezquer M; Ezquer F; Ricca M; Allers C; Conget P J Hepatol; 2011 Nov; 55(5):1112-20. PubMed ID: 21356258 [TBL] [Abstract][Full Text] [Related]
2. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606 [TBL] [Abstract][Full Text] [Related]
3. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695 [TBL] [Abstract][Full Text] [Related]
4. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Cong WN; Tao RY; Tian JY; Liu GT; Ye F Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155 [TBL] [Abstract][Full Text] [Related]
5. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065 [TBL] [Abstract][Full Text] [Related]
7. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014 [TBL] [Abstract][Full Text] [Related]
8. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. Lo L; McLennan SV; Williams PF; Bonner J; Chowdhury S; McCaughan GW; Gorrell MD; Yue DK; Twigg SM J Hepatol; 2011 Aug; 55(2):435-44. PubMed ID: 21184785 [TBL] [Abstract][Full Text] [Related]
10. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026 [TBL] [Abstract][Full Text] [Related]
11. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Tomas E; Wood JA; Stanojevic V; Habener JF Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160 [TBL] [Abstract][Full Text] [Related]
12. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117 [TBL] [Abstract][Full Text] [Related]
13. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. Nakano T; Cheng YF; Lai CY; Hsu LW; Chang YC; Deng JY; Huang YZ; Honda H; Chen KD; Wang CC; Chiu KW; Jawan B; Eng HL; Goto S; Chen CL J Hepatol; 2011 Aug; 55(2):415-25. PubMed ID: 21184788 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102 [TBL] [Abstract][Full Text] [Related]
15. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice. Liu LF; Purushotham A; Wendel AA; Belury MA Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064 [TBL] [Abstract][Full Text] [Related]
16. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. Asano T; Watanabe K; Kubota N; Gunji T; Omata M; Kadowaki T; Ohnishi S J Gastroenterol Hepatol; 2009 Oct; 24(10):1669-76. PubMed ID: 19788607 [TBL] [Abstract][Full Text] [Related]
17. Administration of multipotent mesenchymal stromal cells restores liver regeneration and improves liver function in obese mice with hepatic steatosis after partial hepatectomy. Ezquer F; Bahamonde J; Huang YL; Ezquer M Stem Cell Res Ther; 2017 Jan; 8(1):20. PubMed ID: 28129776 [TBL] [Abstract][Full Text] [Related]
18. Human mesenchymal stem cells towards non-alcoholic steatohepatitis in an immunodeficient mouse model. Winkler S; Borkham-Kamphorst E; Stock P; Brückner S; Dollinger M; Weiskirchen R; Christ B Exp Cell Res; 2014 Aug; 326(2):230-9. PubMed ID: 24786317 [TBL] [Abstract][Full Text] [Related]
19. Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice. Min AK; Kim MK; Kim HS; Seo HY; Lee KU; Kim JG; Park KG; Lee IK Life Sci; 2012 Jan; 90(5-6):200-5. PubMed ID: 22154902 [TBL] [Abstract][Full Text] [Related]
20. Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells has a neutral effect on obesity-induced diabetic cardiomyopathy. Calligaris SD; Conget P Biol Res; 2013; 46(3):251-5. PubMed ID: 24346072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]